Bio Ventures to Oversee Alnylam, GSK IP Pool for Neglected Disease Research | GenomeWeb

Alnylam Pharmaceuticals and GlaxoSmithKline have selected non-profit Bio Ventures for Global Health to oversee the an intellectual property pool that the companies formed last year to assist with the discovery and development of new treatments for neglected tropical diseases.

"By adopting a more accessible approach to intellectual property, the pool facilitates access to compounds and technologies and, most importantly, industrial know-how for organizations that want to conduct research on treatments for these neglected diseases," the companies said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.